5 completed, 2 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Malignant Ovarian Mixed Epithelial Tumor: new trials by email Literature Review of Malignant Ovarian Mixed Epithelial Tumor trials Research Report on Malignant Ovarian Mixed Epithelial Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Acetyl-L-Carnitine Hydrochloride, Placebo, Questionnaire Administration - Fatigue, Malignant Ovarian Mixed Epithelial Tumor | Phase 3 | Withdrawn | Gynecologic Oncology Group | 2012-04-01 | 2014-12-31 | |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Carboplatin, Paclitaxel Poliglumex, Pharmacological Study - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 32 | 2003-04-01 | 2015-05-08 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Carboplatin, Cyclophosphamide, Filgrastim - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Terminated | Gynecologic Oncology Group | 12 | 1999-11-01 | 2017-08-09 |
Ovarian Neoplasms (8) · Brenner Tumor (7) · Fallopian Tube Neoplasms (7) · Neurotoxicity Syndromes (2) · Fatigue (1) · Pain (1)
Adnexal Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Gonadal Disorders (8) · Neoplasms (8) · Neoplasms by Site (8) · Ovarian Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Fallopian Tube Diseases (7)
Paclitaxel (4) · Taxes (4) · Carboplatin (3) · Bevacizumab (1) · Cisplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Peripheral Blood Stem Cell Transplantation (1) · Topotecan (1) · VTX-2337 (1) · paclitaxel poliglumex (1)
Gynecologic Oncology Group (7) · National Cancer Institute (NCI) (1)
United States (7) · Canada (1) · Japan (1) · South Korea (1)
Bradley Monk (1) · David Kushner (1) · Don Dizon (1) · Katherine Bell-McGuinn (1) · Mark Morgan (1) · Michael Gold (1) · Robert Burger (1) · Russell Schilder (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 29550184, PMID 31216226, PMID 35144591, PMID 36252167, PMID 37185961
U10CA027469 (7), U10CA180868 (2), U10CA101165 (1)